Integrative Analysis of Human Glioblastoma Multiforme

Tongji University

Status: Enrolling

Conditions: GBM

Treatments: Other: Normal brain tissue

Study type: Observational

Funder types: Other

Identifiers

NCT03005132

2016-521-Rainy

Details and patient eligibility

About

Integrative analysis of GBM

Full description

The investigators will analyzed proteomes of paired normal brain tissues and GBM, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal brain tissue, primary GBM carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of GBM characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≤ 75 years with histologically proven GBM
• No severe major organ dysfunction
• World Health Organization (WHO) performance status of 0 or 1
• No prior cancer chemotherapy

Exclusion criteria

• Age ≥ 76
• Severe major organ dysfunction
• WHO performance status of >1
• Prior cancer chemotherapy

Trial design

1,000 participants in 3 patient groups

Normal brain tissue

Description:

Normal brain tissue from GBM patients

Treatment:

Other: Normal brain tissue

GBM tissues

Description:

GBM tissues from GBM patients

Treatment:

Other: Normal brain tissue

Metastasis tissues

Description:

Metastasis tissues from GBM patients

Treatment:

Other: Normal brain tissue